To read the full story, subscribe or sign in.

V-Wave kicks off enrollment in pivotal study of device for HF

Oct. 4, 2018

Israeli startup V-Wave Ltd. reported the start of enrollment in a study of a minimally invasive device to treat patients with New York Heart Association (NYHA) class III and ambulatory class IV symptomatic heart failure (HF).

BioWorld MedTech

Today's news in brief

BioWorld

BioWorld briefs for Jan 5, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 5, 2026.

AND-017 increases RBC and hemoglobin in sickle cell disease

BioWorld Science

Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...

3D rendering of antibody drug conjugated with cytotoxic payload

ADCs’ breakout 2025 and their still-unfinished potential

BioWorld Science

Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...

Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact

BioWorld

Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...